Sarcopenia in Metastatic Colorectal Carcinoma.

Area of Science:

• Oncology
• Geriatrics
• Muscle Physiology

Background:

• Sarcopenia, the loss of skeletal muscle mass (SMM), is prevalent in malignancies, particularly metastatic colorectal cancer (mCRC), affecting 30-60% of patients.
• It is a multifactorial condition linked to inflammation, aging, poor nutrition, inactivity, and cancer treatments.
• Sarcopenia is a significant predictor of survival and treatment toxicity in mCRC patients.

Purpose of the Study:

• To investigate the impact of different treatment regimens on skeletal muscle mass in patients with mCRC.
• To compare the effects of regorafenib versus trifluridine/tipiracil on SMM.
• To highlight the clinical significance of SMM changes during mCRC treatment.

Main Methods:

• Analysis of skeletal muscle mass (SMM) changes in patients undergoing various mCRC treatment regimens.
• Routine imaging techniques for sarcopenia detection and quantification.
• Comparison of SMM changes between patients receiving regorafenib and those receiving trifluridine/tipiracil.

Main Results:

• Skeletal muscle mass generally decreases during intensive mCRC treatment regimens.
• SMM tends to increase during low-intensity maintenance therapy or in stable disease.
• Third-line regorafenib therapy was associated with greater skeletal muscle loss compared to trifluridine/tipiracil chemotherapy.

Conclusions:

• Skeletal muscle mass changes dynamically during mCRC treatment, influenced by disease status and therapy.
• Regorafenib may lead to more significant skeletal muscle loss than trifluridine/tipiracil, potentially affecting patient survival and quality of life.
• Further prospective studies are required to fully understand the implications of SMM alterations in mCRC management.